Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

[1]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Herman,et al.  A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects , 2009, Journal of clinical pharmacology.

[4]  J. Blay,et al.  Trabectedin for the management of soft-tissue sarcoma , 2009, Expert review of anticancer therapy.

[5]  M. Malik,et al.  Electrocardiographic QTc Changes Due to Moxifloxacin Infusion , 2009, Journal of clinical pharmacology.

[6]  G. Mannens,et al.  In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. , 2009, Biochemical pharmacology.

[7]  M. Silkey,et al.  Period Correction of the QTc of Moxifloxacin With Multiple Predose Baseline ECGs Is the Least Variable of 4 Methods Tested , 2009, Journal of clinical pharmacology.

[8]  J. Schellens,et al.  Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). , 2009, Current clinical pharmacology.

[9]  Lawrence J Hickey,et al.  The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies , 2008, Clinical pharmacology and therapeutics.

[10]  J. Wagner,et al.  Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval , 2008, Journal of clinical pharmacology.

[11]  J. Blay,et al.  Trabectedin and its potential in the treatment of soft tissue sarcoma , 2008, Therapeutics and clinical risk management.

[12]  D. Rosillon,et al.  Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study , 2007, European Journal of Clinical Pharmacology.

[13]  J. Pérez-Ruixo,et al.  Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis®) in Cancer Patients , 2007, Clinical pharmacokinetics.

[14]  S. Keam,et al.  Trabectedin , 2012, Drugs.

[15]  Borje Darpo,et al.  Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.

[16]  V. Semiglazov,et al.  Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens , 2005 .

[17]  F. D. De Braud,et al.  Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[19]  Joel Morganroth,et al.  Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development. , 2004, Journal of electrocardiology.

[20]  R. Shah,et al.  The significance of QT interval in drug development. , 2002, British journal of clinical pharmacology.

[21]  G. Demetri,et al.  Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity , 2002, Cancer Chemotherapy and Pharmacology.